NCT07392814
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07392814
Title Single-Center Phase 1 Study With Escalating Doses of Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia (AML). TOCIVENA (TOCIVENA)
Acronym TOCIVENA
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Nantes University Hospital
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.